Conference Coverage

Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma

08/12/2025

Meghan Mooradian, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which assessed neoadjuvant dostarlimab plus cobolimab among patients with high-risk resectable melanoma. Results demonstrated that this neoadjuvant regimen showed both efficacy and safety in this patient population.

These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

Source:

Mooradian M, Karunamurthy A, Wang H, et al. Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract LBA9504

Recent News

News

Sequential HER2-Targeted Therapy Following Trastuzumab Deruxtecan Discontinuation Among Patients With HER2-Positive Metastatic Breast Cancer

09/12/2025

Stephanie Holland

Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...

Sequential HER2-targeted therapy...

09/12/2025

Oncology

News

Durvalumab Plus Platinum-Based Chemotherapy for Treatment-Naive Patients With Extensive-Stage Small Cell Lung Cancer

09/10/2025

Stephanie Holland

According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...

According to exploratory...

09/10/2025

Oncology

FDA Approval

FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer

09/10/2025

Allison Casey

The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.

The FDA has accepted an NDA for...

09/10/2025

Oncology

News

Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer

09/10/2025

Stephanie Holland

According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.

According to results from a...

09/10/2025

Oncology

FDA Approval

FDA Approves Selumetinib Granules and Capsules for Pediatric Patients With NF1-Associated Symptomatic and Inoperable Plexiform Neurofibromas

09/10/2025

Stephanie Holland

The FDA has approved selumetinib granules and capsules for pediatric patients ≥ 1 year of age with neurofibromatosis type 1 who have symptomatic and inoperable plexiform neurofibromas.

The FDA has approved selumetinib...

09/10/2025

Oncology

News

Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer

08/28/2025

Stephanie Holland

According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.

According to results from a...

08/28/2025

Oncology

News

Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer

08/28/2025

Stephanie Holland

According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.

According to results from the...

08/28/2025

Oncology

News

Dual Immune Checkpoint Blockade Plus Radiotherapy Fails to Improve Outcomes Among Newly Diagnosed Patients With MGMT-Unmethylated Glioblastoma

08/28/2025

Stephanie Holland

According to results from a phase 2 trial, radiotherapy in addition to dual immune checkpoint blockade with ipilmumab and nivolumab failed to improve outcomes compared to radiotherapy plus single-agent temozolomide among newly diagnosed adult...

According to results from a...

08/28/2025

Oncology

News

Intratumoral Clostridium Novyi-Nontoxic Plus Pembrolizumab Demonstrates Clinical Promise Among Patients With Treatment-Refractory Advanced Solid Tumors

08/27/2025

Stephanie Holland

According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.

According to results from a...

08/27/2025

Oncology

News

Afatinib Plus Carboplatin and Pemetrexed Demonstrates Efficacy, Safety Among Patients WIth Advanced EGFR-Mutated Non-Small Cell Lung Cancer

08/27/2025

Stephanie Holland

According to results from the NEJ025B study, afatinib plus carboplatin and pemetrexed demonstrated promising efficacy and safety among patients with EGFR-mutated advanced non-small cell lung cancer who experienced disease progression after...

According to results from the...

08/27/2025

Oncology